Perspectives on Statistical Strategies for the Regulatory Biomarker Qualification Process
Suzanne Hendrix, Robin Mogg, Sue J Wang, Aloka Chakravarty, Klaus Romero, Samuel P. Dickson, John‐Michael Sauer, Lisa M. McShane
Abstract
Qualification of a biomarker for use in a medical product development program requires a statistical strategy that aligns available evidence with the proposed context of use (COU), identifies any data gaps to be filled and plans any additional research required to support the qualification. Accumulating, interpreting and analyzing available data is outlined, step-by-step, illustrated by a qualified enrichment biomarker example and a safety biomarker in the process of qualification. The detailed steps aid requestors seeking qualification of biomarkers, allowing them to organize the available evidence and identify potential gaps. This provides a statistical perspective for assessing evidence that parallels clinical considerations and is intended to guide the overall evaluation of evidentiary criteria to support a specific biomarker COU.